Peel Hunt reiterated their hold rating on shares of BTG (LON:BTG) in a research note released on Wednesday morning. Peel Hunt currently has a GBX 700 ($9.83) price objective on the stock.
Other equities research analysts have also recently issued reports about the stock. Numis Securities reiterated a buy rating and set a GBX 900 ($12.63) price target on shares of BTG in a research report on Friday, December 8th. Shore Capital upgraded shares of BTG to a buy rating in a research report on Monday, March 26th. Finally, JPMorgan Chase reiterated a neutral rating on shares of BTG in a research report on Monday, January 15th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. BTG has a consensus rating of Buy and a consensus price target of GBX 774.71 ($10.87).
Shares of BTG opened at GBX 607.50 ($8.53) on Wednesday. BTG has a 1-year low of GBX 559.82 ($7.86) and a 1-year high of GBX 784 ($11.01).
COPYRIGHT VIOLATION NOTICE: “BTG’s (BTG) Hold Rating Reiterated at Peel Hunt” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/btgs-btg-hold-rating-reiterated-at-peel-hunt-2.html.
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.